Clinical Trial Update: Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and tolerability of aripiprazole in adolescents with schizophrenia and in children/adolescents with Bipolar I Disorder (ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features | Phase 3 | Status: TERMINATED | Results posted: 2016-02-08